Phoenix Arises: Revolutionary CAR-T Obliterates End-Stage Lymphoma After Seven Failed Treatments

A patient battling relentless follicular lymphoma, after seven prior treatments failed, achieves an astonishing complete remission.
The novel BAFF-R targeting CAR-T therapy, PMB-CT01, demonstrates a flawless 100% complete response rate in all seven patients treated to date.
This breakthrough occurs with a remarkable safety profile, notably sparing this heavily pre-treated patient from severe, common CAR-T side effects.

For one follicular lymphoma patient, the end of the road seemed near. Seven grueling lines of therapy—chemoimmunotherapies, even advanced CD19 CAR T-cells, investigational antibodies, and antibody-drug conjugates—had all been exhausted, powerless against the relapsed/refractory (r/r) disease³. Follicular lymphoma, though often termed "slow-growing," is an unyielding adversary, historically deemed incurable, where each relapse steals more hope and shortens time.

Then, a beacon pierced the darkness: PMB-CT01.

In a seismic announcement from PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI), this very patient, against crushing odds, achieved complete remission just one month post-treatment with their innovative BAFF-R targeting CAR T-cell therapy³. This is no solitary victory; this individual joins six others in the PMB-102 study, pushing the tally to seven patients—all seven reaching a 100% complete response rate with durable effects and, critically, a manageable safety profile⁴. Astoundingly, this warrior, despite their extensive prior treatments, experienced no Cytokine Release Syndrome (CRS) or ICANS—debilitating side effects often shadowing CAR-T therapies³.

PMB-CT01 is not merely an iteration; it's a paradigm shift. It hones in on BAFF-R, a receptor vital for B-cell survival that cancer cells are less likely to discard, a stark contrast to CD19, which can be lost, rendering treatments ineffective^{3, 5}. Indeed, preclinical studies hinted at its superior might against certain lymphomas, even those that had shed CD19^{1, 5}. "Most of the PMB-102 trial participants relapsed after CD19 CAR T therapy and/or presented with CD19 negative tumors," stated Hazel Cheng PhD., COO of PeproMene Bio. "PMB-CT01 could present a viable alternative option for patients facing this challenging scenario."

This first-in-class therapy forges a new path for patients cornered by B-cell malignancies, especially those whose cancers have learned to evade CD19-directed attacks. As PeproMene Bio courageously advances its study into a multi-site expansion⁴, a new dawn of potent, safer cancer annihilation may be breaking.

Phoenix Arises: Revolutionary CAR-T Obliterates End-Stage Lymphoma After Seven Failed Treatments

References

Stay Updated!